Improving performance of multigene panels for genomic analysis of cancer predisposition

Genetics in Medicine

Volumn 18, Issue 10, 2016, Pages 974-981

  Shirts, Brian H ^a   Casadei, Silvia ^b   Jacobson, Angela L ^a   Lee, Ming K ^b   Gulsuner, Suleyman ^b   Bennett, Robin L ^b   Miller, Margaret ^c   Hall, Sarah A ^d   Hampel, Heather ^e   Hisama, Fuki M ^b   Naylor, Lorraine V ^b   Goetsch, Cathleen ^f   Leppig, Kathleen ^b,g   Tait, Jonathan F ^a   Scroggins, Sheena M ^a   Turner, Emily H ^a   Livingston, Robert ^a   Salipante, Stephen J ^a   King, Mary Claire ^a,b   Walsh, Tom ^b   Pritchard, Colin C ^a   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Providence Alaska Medical Center   (United States)

^d Kadlec Regional Medical Center   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Cancer   (United States)

^g CENTER FOR HEALTH STUDIES   (United States)

Author keywords

genetic counseling; genetic testing; hereditary cancer syndromes; hereditary nonpolyposis; incidental findings

Indexed keywords

GENOMIC DNA; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; BROCA GENE; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; COLOSEQ GENE; DIAGNOSTIC VALUE; FAMILY HISTORY; FEMALE; GENE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CONSERVATION; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH THROUGHPUT SEQUENCING; HUMAN; INCIDENTAL FINDING; INTRADUCTAL CARCINOMA; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; MULTIPLE CANCER; NEUROECTODERM TUMOR; OVARY CANCER; PRACTICE GUIDELINE; SERTOLI CELL TUMOR; TUMOR GENE; ADULT; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; RISK FACTORS;

EID: 84989836663     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.212     Document Type: Article

References (34)

1. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010;107:12629-12633.
2. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011;108:18032-18037.
3. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012;14:357-366.
4. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 2014;12:1339-1346.
5. Gallego CJ, Shirts BH, Bennette CS, et al. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. J Clin Oncol 2015;33:2084-2091.
6. Yorczyk A, Robinson LS, Ross TS. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clin Genet 2014;16:12488.
7. Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 2014;86:510-520.
8. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014;311:1035-1045.
9. Laduca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014;24:40.
10. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiplegene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014;14:14.
11. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2014;3:29010.
12. Maxwell KN, Wubbenhorst B, D'Andrea K, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med 2014;11:176.
13. Plon SE, Eccles DM, Easton D, et al.; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-1291.
14. Shirts BH, Walsh T, Jacobson A, et al. Performance characteristics of collaborative, multiple-director sign-out for next-generation sequencing tests. J Mol Diagn 2013;15:845G08.
15. University of Washington. UW Laboratory Medicine Clinical Test Information. Previous Versions of BROCA-Cancer Risk Panel. http://web.labmed. washington.edu/tests/genetics/BROCA-VERSIONS. Accessed 28 January 2014.
16. University of Washington. UW Laboratory Medicine Clinical Test Information. Previous Versions of ColoSeq™-Lynch and Polyposis Panel. http://web. labmed.washington.edu/tests/genetics/COSEQ-VERSIONS. Accessed 28 January 2014.
17. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014;16:56-67.
18. Baudhuin LM, Lagerstedt SA, Klee EW, Fadra N, Oglesbee D, Ferber MJ. Confirming variants in next-generation sequencing panel testing by Sanger sequencing. J Mol Diagn 2015;17:456-461.
19. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. Classification of rare missense substitutions, using risk surfaces, with genetic-And molecular-epidemiology applications. Hum Mutat 2008;29:1342-1354.
20. Le Calvez-Kelm F, Lesueur F, Damiola F, et al.; Breast Cancer Family Registry. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res 2011;13:R6.
21. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet 2013;9:e1003709.
22. Fu W, Gittelman RM, Bamshad MJ, Akey JM. Characteristics of neutral and deleterious protein-coding variation among individuals and populations. Am J Hum Genet 2014;95:421-436.
23. Xue Y, Chen Y, Ayub Q, et al.; 1000 Genomes Project Consortium. Deleteriousand disease-Allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 2012;91:1022-1032.
24. Starita LM, Young DL, Islam M, et al. Massively parallel functional analysis of BRCA1 RING domain variants. Genetics 2015;200:413-422.
25. Chong HK, Wang T, Lu HM, et al. The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay. PLoS One 2014;9:e97408.
26. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in highrisk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011;13:R20.
27. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-311.
28. Shirts BH, Salipante SJ, Casadei S, et al. Deep sequencing with intronic capture enables identification of an APC exon 10 inversion in a patient with polyposis. Genet Med. 2014;27:30.
29. Plazzer JP, Sijmons RH, Woods MO, et al. The InSiGHT database: utilizing 100 years of insights into Lynch syndrome. Fam Cancer 2013;12:175-180.
30. International Agency for Research on Cancer. IARC TP53 Database. http://p53. iarc.fr/. Accessed 19 January 2015.
31. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42:D980-D985.
32. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;5:30.
33. Richards CS, Bale S, Bellissimo DB, et al.; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008;10:294-300.
34. Dorschner MO, Amendola LM, Turner EH, et al.; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Actionable, pathogenic incidental findings in 1,000 participants? exomes. Am J Hum Genet 2013;93:631-640.